EVD is highly contagious, with high morbidity and mortality. All healthcare workers and institutions need to maintain a high level of suspicion in order to quickly identify patients at risk for EVD. It is imperative that clinicians also consider other common childhood illnesses, including endemic tropical diseases, while evaluating for and testing for EVD. Early recognition of likely cases and utilization of appropriate PPE are extremely important in order to contain the infection. EVD staff should be trained and monitored in Ebola-specific, appropriate use of PPE. Patients suspected of having symptoms of EVD should be aggressively resuscitated while also initiating supportive measures. Since there is no approved Ebola-specific prophylaxis or treatment, supportive care remains the cornerstone of treatment, with prevention of intravascular depletion, blood pressure support, oxygenation/ventilator support, pain control, nutrition support, and treatment of secondary infections. Additional research is needed to improve outcomes and decrease mortality from this deadly disease, and to reduce the burden of EVD epidemics, especially as they relate to children.
Marlie Dulaurier, MD;Katherine Moyer, DO;Rebecca Wallihan, MD
July 2, 2016
August 2, 2019
4 AMA PRA Category 1 Credits™, 4 ACEP Category I Credits, 4 AAFP Prescribed Credits, 4 AOA Category 2-A or 2-B Credits. Specialty CME Credits: Included as part of the 4 credits, this CME activity is eligible for 0.5 Pharmacology CME credits